Nkarta, Inc.
NKTX$83M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSOUTH SAN FRANCISCO
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Apr 15, 2027
46wMarket Overview
Stock performance and key metrics
NKTX News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fludarabine, Cyclophosphamide | Phase 2 | Lupus Nephritis | - | - |
NKX019 | Phase 2 | Systemic Sclerosis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply